MEI Pharma announced its first LTC purchase, sparking a rally for one of the oldest and well-established crypto coins.

San Diego-based MEI Pharma (NASDAQ:MEIP) has acquired 929,548 Litecoin (CRYPTO: LTC) tokens, becoming the first U.S.-listed ...

Analysts told Decrypt though ETF approval rumors are adding to optimism, it’s MEI Pharma’s buy-in last month that is really ...

EDT MEI Pharma (MEIP) files to sell 25.3M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, ...

An update from MEI Pharma ( (MEIP) ) is now available.

GSR, crypto’s capital markets partner, today announced an investment and strategic partnership with MEI Pharma, Inc. (NASDAQ:MEIP) (“MEI”), in which it will serve as both strategic advisor and digital ...

Consensus from 7 of the American Biotechs analysts is that MEI Pharma is on the verge of breakeven. They expect the company to post a final loss in 2023, before turning a profit of US$8.4m in 2024.

Shares of MEI Pharma were last trading up 17% at $1.95, with a 52-week trading range of $1.23 to $2.28.

MEI Pharma had cash and cash equivalents of $36.2 million as of March 31, 2018. It was anticipating at first that its cash would be enough until the 1st half of its calendar 2019.

MEI Pharma has a 52-week trading range of $1.87 to $13.98. Keep in mind that Monday was the day that the 52-week low was hit, and shares had been at $6.30 on Friday’s closing bell.

SAN DIEGO and TOKYO, April 14, 2020/ PRNewswire/-- MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. today jointly announced that the companies have entered into a global license, development and ...